LDS/Medical Tests/Anaplastic Lymphoma Kinase (ALK) Gene Mutation Analysis

Anaplastic Lymphoma Kinase (ALK) Gene Mutation Analysis

Anaplastic lymphoma kinase (ALK) gene is located on the short arm (p) of chromosome 2 (2p23.2-p23.1). Mutations involving replacement of the amino acid arginine with the amino acid glutamine at position 1275 has been found commonly in both inherited and somatic types of neuroblastoma. Most mutations are acquired rather than inherited. Rarer mutations involve gene amplification, resulting in ALK over expression. Both types of mutation result in uncontrolled proliferation of neuroblasts resulting in neuroblastoma. Inherited mutations of ALK gene follow an autosomal dominant pattern of inheritance and show incomplete penetrance. Neuroblastomas typically present in early childhood with abdominal mass (adrenal involvement), fever, back ache, diarrhea, constipation, flushed skin, chest pain, tachypnea wheezing, hypertension weight loss, proptosis, etc. and may metastasize to various organs like skin and bone.

Anaplastic large cell lymphomas (ALCLs) are rare non-Hodgkin lymphomas originating from the mature post-thymic T-cells. Over 15 rearrangements involving the ALK gene have been implicated in the pathogenesis of ALCL. Patients present with lymphadenopathy, anemia and thrombocytopenia. In advanced cases there may be extra nodal involvement of skin, lung, liver, soft tissue, spleen and bone. Based on the presence of translocations involving ALK, ALCLs are classified as either ALK positive or ALK negative. ALK-positive ALCL responds favorably to chemotherapy and have better outcomes than ALK-negative lymphomas.

Translocations of the ALK gene have also been identified in inflammatory myofibroblastic tumor (IMT; also known as plasma cell granuloma, inflammatory pseudotumor, fibrous histiocytoma, fibroxanthoma and xanthogranuloma . Lastly, inversion of chromosome 2 resulting in fusion of the ALK gene with EML4 gene has been implicated in the pathogenesis of non-small cell lung cancer.

Neuroblastoma

  • In diagnosis of hereditary neuroblastomas.
  • Prenatal assessment for neuroblastoma in pregnancy
  • To screen for neuroblastoma before IVF

Anaplastic large cell lymphomas

  • To diagnose and classify Anaplastic large cell lymphomas.
  • To assess prognosis of Anaplastic large cell lymphomas.
  • To plan treatment protocols in Anaplastic large cell lymphomas.

Others

  • In diagnosis of hereditary inflammatory myofibroblastic tumor and non-small cell lung cancer.
  • Individuals with mutations of ALK gene are at higher risk for development of neuroblastomas
  • Mutation involving replacement of the amino acid arginine with the amino acid glutamine at position 1275 or gene amplification of ALK gene and/or alanine repeat expansion in exon 3 of PHOX2B gene confirms the diagnosis of neuroblastoma.
  • ALK translocations involving chromosome 2 aid in diagnosis of hereditary inflammatory myofibroblastic tumor, non-small cell lung cancer and Anaplastic large cell lymphomas.

Negative for mutation analyze (No reportable pathogenic variants were identified)

Polymerase chain reaction, Sequencing, Gene-targeted deletion/duplication analysis, gel electrophoresis.

Whole Blood EDTA (Lavender) or Heparin (Green)

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable

Saliva

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: up to 1 month

Buccal Swab

Stability

  • Ambient: 5-7 days
  • Refrigerated: 7-14 days
  • Frozen: up to 1 month
B-Type Natriuretic Peptide (BNP), Cerebrospinal Fluid Microscopic Evaluation, 1p/19q Deletion in Gliomas, FISH, Brain biopsy.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login